3.20
0.88%
-0.0285
アフターアワーズ:
3.20
Cosciens Biopharma Inc (CSCI) 最新ニュース
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - Houston Chronicle
COSCIENS Biopharma Advances Merger and Pipeline - TipRanks
Shimmick Announces New CEO - The Manila Times
COSCIENS Biopharma Inc. Reports Third Quarter 2024 - GlobeNewswire
COSCIENS Q3 Loss Widens to $5.8M, Discontinues Key Programs Amid Pipeline Shift | CSCI Stock News - StockTitan
CSCI stock touches 52-week low at $3.4 amid market fluctuations - Investing.com India
Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market InsightsTechnavio - PR Newswire
Cosciens Biopharma (TSX:CSCI) EPS without NRI : C$-4.32 (TTM As of Jun. 2024) - GuruFocus.com
AEterna Zentaris : March 10, 2015 Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015 - Marketscreener.com
Yorvipath-finders? Septerna, others forge on in hypothyroidism - BioWorld Online
Cosciens Biopharma (FRA:ET8) Enterprise Value : €-13.18 Mil (As of Oct. 17, 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cash From Discontinued Investi - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Profitability Rank : 5 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Shares Outstanding (EOP) : 3.06 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Free Cash Flow : €-5.76 Mil (TTM As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Long-Term Debt & Capital Lease Obligation : €1.19 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Inventory-to-Revenue : 1.40 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) 3-Year Revenue Growth Rate : -13.80% (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cyclically Adjusted PS Ratio : 0.56 (As of Oct. 16, 2024) - GuruFocus.com
The Escalator: Syneos Health, The FDA, Pfizer and more - MM+M Online
COSCIENS Biopharma streamlines board with resignation By Investing.com - Investing.com Canada
COSCIENS Biopharma reshuffles board of directors By Investing.com - Investing.com South Africa
COSCIENS Biopharma streamlines board with resignation - Investing.com
COSCIENS Biopharma reshuffles board of directors - Investing.com India
Cosciens Biopharma director Carolyn Egbert resigns - TipRanks
COSCIENS Biopharma Restructures Board After Resignation - TipRanks
COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewswire
AgEagle Aerial Systems Inc. Announces Closing of $6.5 Million Public Offering - The Manila Times
COSCIENS Biopharma names new board director By Investing.com - Investing.com South Africa
COSCIENS Biopharma names new board director - Investing.com
COSCIENS Biopharma Welcomes New Board Director - TipRanks
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - The Manila Times
Cintas (NASDAQ:CTAS) Reaches New 12-Month High at $209.59 - MarketBeat
Cintas Stock Hits All-Time High Amid Strong Results, Outlook Lift - MSN
Cintas stock soars to all-time high, hits $209.13 - Investing.com India
Cintas rises on raising annual profit, revenue forecasts - XM
Cintas’s shares rise on improved earnings guidance (NASDAQ:CTAS) - Seeking Alpha
Cintas Beats Q1 Earnings On Margin Strength, Boosts Outlook - Yahoo Finance UK
Cintas earnings beat by $0.10, revenue topped estimates - Investing.com Australia
Cintas (NASDAQ:CTAS) Releases FY25 Earnings Guidance - Defense World
Cintas stock gains 2% on Q1 earnings beat, raises full-year outlook - Investing.com Australia
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Buys 6,562 Shares of Cintas Co. (NASDAQ:CTAS) - Defense World
Colombia defeats ICSID case over internet domain name - Latin Lawyer
Scalar Gauge Management LLC Decreases Stock Position in Cintas Co. (NASDAQ:CTAS) - Defense World
Why Carpenter Tech (CRS) Stock is Surging Despite Boeing's (BA) Troubles - GuruFocus.com
COSCIENS Biopharma announces management changes, integration progress - Investing.com
Toronto Stocks Flat; Bitfarms Up on Settlement with Riot Platforms - Marketscreener.com
Cosciens Biopharma Shares Fall on ALS Treatment Research End, Cost Cutting - MarketWatch
Cosciens Biopharma provides update on development projects - TipRanks
Cosciens Biopharma provides update on merger integration, succession plans - TipRanks
COSCIENS Biopharma Advances Merger and Seeks New Leadership - TipRanks
COSCIENS Biopharma Inc. Provides Updates on Merger - GlobeNewswire
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs - StockTitan
Cintas Co. (NASDAQ:CTAS) Shares Sold by Pacer Advisors Inc. - Defense World
大文字化:
|
ボリューム (24 時間):